Source-backed guidance for evaluating candidacy for Xeomin and Daxxify botulinum toxin treatments, including contraindications, safety considerations, and consultation preparation.
Last reviewed: 2026-05-06
7 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
Both Xeomin and Daxxify are FDA-approved botulinum toxin type A formulations with distinct formulation characteristics.
Ideal candidates are generally healthy adults without neuromuscular disorders, not pregnant or breastfeeding.
Xeomin offers a pure neurotoxin formulation with lower immunogenicity risk; Daxxify provides extended duration (median 24 weeks).
A thorough medical history review with a qualified provider is essential before treatment.
Educational information only
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
Understanding Xeomin and Daxxify
Xeomin (incobotulinumtoxinA) and Daxxify (daxibotulinumtoxinA) are two FDA-approved botulinum toxin type A formulations used for both therapeutic and aesthetic applications. Both belong to the broader category of neuromodulators, which also includes Botox and Dysport, but each has distinct formulation characteristics that may influence treatment selection. For more information on the broader botulinum toxin hub and treatment overview, visit our dedicated resources [S1].
Xeomin is distinguished by its pure neurotoxin formulation—it contains no accessory proteins, which may contribute to a lower risk of immunogenicity over time. This purification process removes complexing proteins that are naturally present in other formulations. Xeomin has FDA approval for multiple therapeutic indications including cervical dystonia, blepharospasm, and upper limb spasticity in adults [S1].
Daxxify represents a newer advancement in neuromodulator technology. Approved by the FDA in 2022 for glabellar lines, it was the first peptide-formulated botulinum toxin approved for cosmetic use. Daxxify uses a proprietary RTP004 peptide excipient for stability, eliminating the need for human serum albumin as a stabilizer. Clinical trials demonstrated a median duration of 24 weeks for glabellar lines—approximately twice as long as traditional formulations which typically last 12-16 weeks [S2]. Daxxify also received FDA approval for cervical dystonia in August 2023 [S2].
Formulation Differences
The primary distinction between these products lies in their formulation approaches. Xeomin's purification removes accessory proteins, while Daxxify uses a peptide-based stabilization technology. Your provider can help determine which formulation aligns with your treatment goals.
What Makes a Good Candidate
Determining candidacy for Xeomin or Daxxify requires evaluation of several factors. Generally, suitable candidates are adults who wish to address dynamic wrinkles—lines caused by repeated muscle movements—and have realistic expectations about outcomes [S1, S3].
Essential eligibility criteria include:
Being in generally good health without significant neuromuscular conditions
Not currently pregnant or breastfeeding
No known hypersensitivity to botulinum toxin or formulation components
Absence of infection at planned injection sites
Understanding that results vary and may differ from other individuals
Age considerations play a role in candidacy assessment. Younger patients with good skin elasticity and dynamic wrinkles often see excellent results. Older patients may still be candidates, though age-related changes in muscle function and skin quality may influence outcomes and may require adjusted dosing approaches [S1].
Previous treatment history is also relevant. Patients who have used other botulinum toxin products may transition to Xeomin or Daxxify, though providers typically assess response patterns and dosing requirements on an individual basis [S1].
Duration and Results: What to Expect
Understanding expected duration helps set realistic expectations. Daxxify has demonstrated a median duration of 24 weeks for glabellar lines in clinical studies, with the 25th-75th percentile range spanning 19-33 weeks [S2]. This extended duration may appeal to patients seeking fewer treatment sessions per year.
Xeomin typically provides results lasting 3-4 months, consistent with traditional botulinum toxin type A formulations [S1]. Individual response duration varies based on factors including muscle mass, injection technique, metabolism, and treatment area.
Individual Variation
Response duration varies significantly between individuals. Factors such as muscle anatomy, injection technique, dosage, and personal physiology all influence how long results last. Your provider can offer guidance based on typical patterns but cannot guarantee specific duration for any individual.
High response rates have been documented in clinical trials. For Daxxify, more than 96% of participants achieved none or mild severity ratings on standardized assessment scales at peak effect [S2]. Xeomin has demonstrated comparable efficacy to other botulinum toxin type A products in clinical studies [S1].
Safety Considerations and Contraindications
Certain conditions and factors require careful consideration or may contraindicate treatment altogether.
Absolute contraindications include:
Known hypersensitivity to botulinum toxin or any formulation components
Infection at the planned injection site
Pregnancy and breastfeeding [S1, S3]
Neuromuscular junction disorders including myasthenia gravis, Lambert-Eaton syndrome, and amyotrophic lateral sclerosis (ALS) [S1]
Concurrent use of aminoglycoside antibiotics or muscle relaxants, which may enhance botulinum toxin effects [S1, S3]
History of adverse responses to other botulinum toxin products
Certain medications that may affect neuromuscular transmission
Underlying medical conditions that require individual evaluation
Medical Disclosure Essential
Disclose your complete medical history, including all medications, supplements, and health conditions, during your consultation. Certain medications—particularly aminoglycoside antibiotics and muscle relaxants—may interact with botulinum toxin effects. This information helps your provider assess safety and appropriate dosing.
The American Academy of Dermatology emphasizes that patient safety depends on thorough pre-treatment assessment and appropriate provider selection [S3]. Treatment should only be administered by qualified healthcare professionals with training in botulinum toxin injection techniques.
Consultation Checklist: Questions to Ask
Preparing for your consultation helps ensure productive discussions with your provider.
Consider asking these questions:
What experience do you have with both Xeomin and Daxxify specifically?
Which formulation would you recommend for my goals and why?
What results can I realistically expect based on my anatomy?
What are the potential side effects I should know about?
How should I prepare for my appointment?
What should I do if I experience concerns after treatment?
Before your appointment, gather:
Complete medication and supplement list
Known allergies or previous reactions to medications
Medical history including any neuromuscular conditions
List of questions and concerns
Provider Selection
Choosing a qualified provider is essential for safe treatment outcomes. Consider their training, experience with the specific products, and the facility's accreditation. Our care coordination team can help connect you with vetted providers to find a qualified provider or learn more about accredited facilities.
When to Exercise Caution
Certain situations warrant additional consideration before proceeding.
Medical conditions requiring special evaluation:
History of facial surgery or procedures
Significant facial asymmetry
Neurological conditions (even if not listed as absolute contraindications)
Bleeding disorders or blood-thinning medication use
Pregnancy and breastfeeding:
Botulinum toxin treatments are contraindicated during pregnancy and breastfeeding. If you are planning pregnancy, discuss timing considerations with your provider. Treatment can typically be resumed after pregnancy and once breastfeeding has concluded [S1].
Expectation management:
Be cautious of providers who guarantee specific outcomes, offer significantly discounted pricing below market rates, or pressure you to make immediate decisions. Legitimate providers will discuss realistic expectations, potential limitations, and allow time for informed decision-making.
Results vary by individual, and factors such as skin quality, muscle strength, and personal physiology influence outcomes. Your provider can offer guidance based on clinical experience but cannot promise identical results to those seen in promotional materials or on other patients.
Red Flags
Guaranteed outcome claims or "perfect results" promises
Pressure to book immediately without consultation
Unable to provide clear licensing and credentials
No clear protocol for post-treatment concerns or complications
Ready to explore your options? Our care coordination team can help you find qualified providers experienced with Xeomin and Daxxify treatments, answer your questions about the process, and support your planning from consultation through recovery. Discuss your goals with our team to determine whether Xeomin or Daxxify may be appropriate for you.
